Table 5.
Relative risk of cardiovascular outcomes by the VKORC1 and Chr.9p21.3 interactions during a longitudinal follow‐up of stroke patients
| VKORC1 rs2359612 | Chr.9p21.3 rs10757274 | Person‐years | Outcomes, n (%) | Adjusted Hazards ratio (95% CI)* | p value* |
|---|---|---|---|---|---|
| Stroke recurrence | |||||
| TT | AA | 1,293.48 | 49 (16.4%) | 1.00 | |
| TT | AG+GG | 3,272.89 | 169 (21.7%) | 1.45 (1.05–2.00) | .02 |
| CT | AA | 256.46 | 12 (19.7%) | 1.41 (0.75–2.66) | .29 |
| CT+CC | AG+GG | 789.97 | 50 (25.9%) | 1.84 (1.24–2.73) | .003 |
| CVD events | |||||
| TT | AA | 1,231.65 | 61 (20.5%) | 1.00 | |
| TT | AG+GG | 3,089.48 | 194 (24.9%) | 1.32 (0.99–1.76) | .06 |
| CT | AA | 253.16 | 13 (21.3%) | 1.18 (0.65–2.16) | .59 |
| CT+CC | AG+GG | 751.52 | 57 (29.5%) | 1.65 (1.15–2.38) | .007 |
| CVD mortality | |||||
| TT | AA | 1,290.37 | 23 (7.7%) | 1.00 | |
| TT | AG+GG | 3,269.28 | 93 (11.9%) | 1.64 (1.04–2.59) | .04 |
| CT | AA | 271.70 | 3 (4.9%) | 0.74 (0.22–2.48) | .63 |
| CT+CC | AG+GG | 814.07 | 27 (14.0%) | 2.16 (1.24–3.79) | .007 |
Abbreviations: Chr.9p21.3, Chromosome 9p21.3; CVD, cardiovascular diseases; VKORC1, vitamin K epoxide reductase complex subunit 1.
*
Adjusted Hazards ratio (95% CI) and p values were obtained by the Cox regression analysis after adjustment for age, gender, BMI, fasting glucose, triglycerides, total cholesterol, HDL‐cholesterol, LDL‐cholesterol, family history of stroke, systolic and diastolic blood pressure, smoking, and drinking status.